AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Cogent Biosciences Participates in Citi Biopharma Back to School Conference
ByAinvest
Tuesday, Aug 26, 2025 8:05 am ET1min read
Cogent Biosciences, a biotechnology company, announced its participation in a fireside chat at the Citi Biopharma Back to School Conference on September 3, 2025. The company also announced the grants of "inducement" equity awards to two new employees under its 2020 Inducement Plan with a grant date of August 25, 2025. A live webcast will be available on Cogent's website, and a replay will be archived for up to 30 days.
Cogent Biosciences, a biotechnology company focused on developing precision therapies for genetically defined diseases, announced its participation in the Citi Biopharma Back to School Conference on September 3, 2025. The event, scheduled to take place at 9:00 a.m. ET, will feature a live webcast available on the company's investor relations website. A replay of the webcast will be accessible for 30 days following the event.Additionally, Cogent Biosciences granted "inducement" equity awards to two new employees under its 2020 Inducement Plan, with a grant date of August 25, 2025. The awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4) and consist of nonqualified options to purchase 54,500 shares of common stock. Each option has a 10-year term, an exercise price equal to the closing price of Cogent's common stock on the grant date, and a four-year vesting schedule with 25% vesting after one year and the remainder vesting in equal monthly installments over the subsequent 36 months, provided the employees remain employed through each vesting date [1].
Cogent Biosciences is based in Waltham, MA and Boulder, CO, and its most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation, among others. The company is also conducting a Phase 1 study of its novel internally discovered FGFR2/3 inhibitor and developing a portfolio of novel targeted therapies for conditions such as systemic mastocytosis and gastrointestinal stromal tumors (GIST) [2].
For more information, visit Cogent Biosciences' website at www.cogentbio.com.
References:
[1] https://www.stocktitan.net/news/COGT/cogent-biosciences-announces-participation-in-the-citi-biopharma-e7erx9ck960t.html
[2] https://www.stocktitan.net/news/COGT/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet